These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24395440)

  • 1. Reply to: Assessing physico-chemical compatibility of concomitantly diluted antiemetics including palonosetron-HCl and fosaprepitant dimeglumine.
    Duersch B
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):437. PubMed ID: 24395440
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing physico-chemical compatibility of concomitantly diluted antiemetics including palonosetron-HCl and fosaprepitant dimeglumine.
    Lipp HP; Gfrörer W
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):435-6. PubMed ID: 24220934
    [No Abstract]   [Full Text] [Related]  

  • 3. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
    Sun S; Schaller J; Placek J; Duersch B
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):509-13. PubMed ID: 23860958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Binding of Palonosetron and Other Antiemetic Drugs to the Serotonin 5-HT3 Receptor.
    Zarkadas E; Zhang H; Cai W; Effantin G; Perot J; Neyton J; Chipot C; Schoehn G; Dehez F; Nury H
    Structure; 2020 Oct; 28(10):1131-1140.e4. PubMed ID: 32726573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection.
    Wu G; Powers D; Yeung S; Chen F
    Int J Pharm Compd; 2018; 22(1):76-85. PubMed ID: 29385388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride.
    Wu G; Powers D; Yeung S; Chen F; Neelon K
    Int J Pharm Compd; 2018; 22(1):86-94. PubMed ID: 29385389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
    Rapoport BL; Jordan K; Weinstein C
    Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
    Adra N; Albany C; Brames MJ; Case-Eads S; Johnson CS; Liu Z; Fausel CA; Breen T; Hanna NH; Hauke RJ; Picus J; Einhorn LH
    Support Care Cancer; 2016 Jul; 24(7):2837-42. PubMed ID: 26838019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical and chemical stability of palonosetron HCl in 4 infusion solutions.
    Trissel LA; Xu QA
    Ann Pharmacother; 2004 Oct; 38(10):1608-11. PubMed ID: 15328393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
    Garnock-Jones KP
    Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
    Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
    J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
    Darmani NA; Zhong W; Chebolu S; Mercadante F
    Pharmacol Biochem Behav; 2015 Apr; 131():104-11. PubMed ID: 25687374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT
    Kovac AL
    Drugs; 2016 Dec; 76(18):1719-1735. PubMed ID: 27988869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM
    Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.
    Tricco AC; Blondal E; Veroniki AA; Soobiah C; Vafaei A; Ivory J; Strifler L; Cardoso R; Reynen E; Nincic V; Ashoor H; Ho J; Ng C; Johnson C; Lillie E; Antony J; Roberts DJ; Hemmelgarn BR; Straus SE
    BMC Med; 2016 Dec; 14(1):216. PubMed ID: 28007031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
    Darmani NA; Zhong W; Chebolu S; Vaezi M; Alkam T
    Eur J Pharmacol; 2014 Jan; 722():2-12. PubMed ID: 24513517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review.
    Tricco AC; Soobiah C; Hui W; Antony J; Struchkov V; Hutton B; Hemmelgarn B; Moher D; Straus SE
    BMC Pharmacol Toxicol; 2015 Jan; 16():1. PubMed ID: 25623303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.